clinical trial · NCT04650555
BIO 300 Oral Powder Safety and Pharmacokinetics
Acute Radiation SyndromeBIO 300 Oral Powder
brief summary
Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.
started
Dec 8, 2020
primary completion
Jul 6, 2021
completion
Jul 6, 2021
last updated
May 3, 2024
official title
A Phase 1 Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profile of BIO 300 Oral Powder in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol